Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

医学 安慰剂 月经 人口 不利影响 内科学 妇科 病理 替代医学 环境卫生
作者
Elizabeth T. Loggers,Rashmi K Chugh,Noah C. Federman,Lee P. Hartner,Richard F. Riedel,Sunny Cho,David L. Hyslop,Allison Lim,Ana Belen Oton,Kutluk Oktay
出处
期刊:Cancer [Wiley]
卷期号:130 (16): 2812-2821 被引量:15
标识
DOI:10.1002/cncr.35324
摘要

INTRODUCTION: Nirogacestat is a targeted gamma secretase inhibitor approved in the United States for adults with progressing desmoid tumors. In the phase 3 DeFi study (NCT03785964) of nirogacestat, ovarian toxicity (OT) was identified as a safety signal among females of reproductive potential (FORP). This analysis further describes the incidence, presentation, and resolution of OT. METHODS: Patients were randomized to twice-daily oral nirogacestat (150 mg) or placebo, taken in continuous 28-day cycles. Investigator-identified OT in FORP was based on abnormal reproductive hormone values or perimenopausal symptoms (or both). Adverse event follow-up was conducted to assess OT resolution. Post hoc analyses included return of menstruation and return of follicle-stimulating hormone (FSH) to within normal limits (WNL) (≤20.4 mIU/mL). RESULTS: Of 92 randomized females, 73 in the safety population were FORP (n = 36 nirogacestat, n = 37 placebo). OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks. Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment. Resolution was reported in 10 of 14 (71%) while on nirogacestat; of these, all 10 experienced return of menstruation and seven had FSH WNL. Two patients were lost to follow-up. CONCLUSION: Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被科研通管家采纳,获得10
刚刚
大模型的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
ding的应助被花开丁帅气采纳,获得10
1秒前
1秒前
科研小白完成签到,获得积分10
2秒前
sun发布了新的文献求助10
2秒前
3秒前
十一完成签到 ,获得积分10
3秒前
4秒前
上官若男的应助被Theprisoners采纳,获得10
4秒前
追寻梦松完成签到,获得积分10
4秒前
山晴发布了新的文献求助10
4秒前
领导范儿的应助被小红采纳,获得10
4秒前
5秒前
今后的应助被佚名采纳,获得10
5秒前
Kyle发布了新的文献求助10
5秒前
5秒前
科研通AI65的应助被灵巧的乌采纳,获得10
5秒前
orixero的应助被mmm采纳,获得10
6秒前
7秒前
sheryy发布了新的文献求助10
7秒前
7秒前
8秒前
dyuguo3完成签到 ,获得积分10
8秒前
求知完成签到,获得积分10
8秒前
weijing发布了新的文献求助10
8秒前
8秒前
9秒前
West发布了新的文献求助10
10秒前
st5114发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
小SCI发布了新的文献求助10
11秒前
平常迎天发布了新的文献求助30
11秒前
11秒前
hwl发布了新的文献求助10
11秒前
bbuullee完成签到,获得积分20
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183730
求助须知:如何正确求助?哪些是违规求助? 9572975
关于积分的说明 21828453
捐赠科研通 7780887
什么是DOI,文献DOI怎么找? 3434086
关于科研通互助平台的介绍 2558276
邀请新用户注册赠送积分活动 2480557